Solanezumab

Drug Profile

Solanezumab

Alternative Names: Anti-amyloid-beta monoclonal antibody - Eli Lilly; Anti-Aβ monoclonal antibody - Eli Lilly; LY-2062430

Latest Information Update: 30 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Eli Lilly
  • Class Antidementias; Monoclonal antibodies
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 01 May 2017 Eli Lilly terminates the phase III ExpeditionPRO trial in Alzheimer's disease (In the elderly, Mid-stage disease) in USA, Belgium, the Netherlands, Canada, Japan, Poland, United Kingdom, Finland, France, Germany, Italy, Puerto Rico, Spain, Sweden and Taiwan (NCT02760602)
  • 07 Mar 2017 Eli Lilly terminates the phase III EXPEDITION3 trial in Alzheimer's disease (In the elderly, Mild dementia due to AD) in USA, Australia, Canada, France, Germany, Italy, Poland, Spain, Sweden, Japan and United Kingdom due to failure to meet the primary endpoint (NCT01900665)
  • 07 Mar 2017 Eli Lilly terminates the extension phase III EXPEDITION EXT trial in Alzheimer's disease in USA, Argentina, Australia, Brazil, Canada, France, Germany, Italy, Japan, South Korea, Poland, Russia, Spain, Sweden, Taiwan and United Kingdom (NCT01127633)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top